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Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125
(CA 125) in mucinous ovarian tumours
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Summary A tumour-associated trypsin inhibitor (TATI) and the cancer antigen 125 (CA 125) were measured
pre- or peroperatively in 30 patients with mucinous ovarian tumours (10 malignant, two borderline and 18
benign) to investigate the separate and combined use of the two markers as a diagnostic tool. In the malignant
and borderline cases considered as a whole, TATI was elevated in 83% and CA 125 in 50%. The former
marker was increased in one (6%) benign tumour and the latter in another (6%). The combined use of TATI
and CA 125 ensured diagnosis of all malignant and borderline tumours. The specificity was 89% and the
positive predictive value 86%. In conclusion, in the distinction of malignant and borderline mucinous ovarian
tumours from benign ones TATI was a more reliable tumour marker than CA 125. The combined use of
TATI and CA 125 ensured diagnosis of all malignant and borderline tumours in the present series.
The tumour-associated trypsin inhibitor (TATI) has recently
been reported to be a potential tumour marker in mucinous
ovarian carcinomas (Halila et al., 1988). TATI was originally
isolated from the urine of a patient with ovarian cancer
(Stenman et al., 1982). The molecule is a 6,000 Da polypep-
tide, which can be measured in serum using a commercially
available radioimmunoassay. High levels of the polypeptide
have been demonstrated in the cystic fluid of malignant,
borderline and benign mucinous ovarian tumours (Halila et
al., 1987). Furthermore, increased values of TATI have been
registered in the serum of 60% of patients with mucinous
ovarian carcinomas (Halila et al., 1988).
We measured TATI before the primary operation of
patients with malignant, borderline and benign mucinous
ovarian tumours and compared these results with the levels
of cancer antigen 125 (CA 125) (Bast et al., 1981, 1983) in
order to assess the value of TATI, used separately and in
combination with CA 125, as a diagnostic tool.
Materials and methods
TATI and CA 125 were measured in serum drawn pre- or
peroperatively from 30 patients with mucinous ovarian neo-
plasms (10 malignant, two borderline and 18 benign) as
verified by histopathological investigation performed accord-
ing to the WHO criterion.
In the malignant cases, the operation included hystero-
salpingo-oophorectomy, appendectomy and omentectomy
supplemented with histological examination of scrapings
from the abdominal diaphragm and liquid from peritoneal
lavage (Bertelsen et al., 1988). FIGO stage I tumours were
diagnosed in four patients, five had stage III disease and one
stage IV.
TATI was measured by a radioimmunoassay (Farmos
Group Ltd, Oulunsalo, Finland) and values above 21 tLg 1-'
were considered abnormal (Stenman et al., 1982). The
CA 125 measurements were performed by a radio- or
enzyme-immunoassay (Abbott RIA or EIA, Abbott
Laboratories, Chicago, USA). Six samples were analysed by
RIA and 24 by EIA technics. Values above 35 U ml-' were
considered elevated (Bast et al., 1983; Fasquelle et al., 1988).
The assays are commercially available and the manufac-
turers' instructions were followed in performing the
measurements. In a comparative investigation including 43
serum samples with an antigen content varying from 5 to
1,032 U ml1' we have proved a linear correlation between the
results of the two CA 125 assays (Y = 0.746X - 10.43;
r = 0.996; X = RIA, Y = EIA).
The serum samples were stored at - 80'C until analysis
and all measurements were performed in duplicate.
Results
The TATI and CA 125 levels were in the range 7-750 ig 1'
and 5-371 U ml-', respectively (Table I). TATI was in-
creased in eight out of 10 malignant tumours and in both
borderline tumours. In contrast, only half the malignant and
the borderline tumours had increased CA 125 levels. In the
18 benign tumours, positive marker levels were observed in
two cases (TATI, 26 Lg I-'; CA 125, 37 U ml-'). Based on
these results, the TATI and CA 125 levels disclosed malig-
nant and borderline tumours in 83% and 50% of the cases
and the negative predictive values were 89% and 74%,
respectively. The specificity and positive predictive value of
the two markers were much alike (TATI, 94% and 91%;
CA 125, 94% and 86%).
The TATI and CA 125 values were correlated with FIGO
stage (Table II). False negative TATI values were registered
in one FIGO stage I and one stage III tumour. Three stage I
and two stage III tumours gave false negative CA 125 levels.
Table I Preoperative measurements of TATI and CA 125 in
30 mucinous ovarian tumours
TATIa CA 125a
(Olg l- ) (UM/-')
Malignant tumour (n = 10)
Range 12-750 7-371
Increased values 80% (8/10) 50% (5/10)
Borderline tumour (n = 2)
Values 35; 425 8; 76
Increased values 100% (2/2) 50% (1/2)
Benign tumour (n = 18)
Range 7-26 5-37
Increased values 6% (1/18) 6% (1/18)
Sensitivity (%) 83 50
Specificity (%) 94 94
Positive predictive value (%) 91 86
Negative predictive value (%) 89 74
'Upper normal level: TATI, 21 iLg[-'; CA 125, 35 Uml'.
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Table II TATI and CA 125 correlated with FIGO stage in ten
malignant mucinous tumours
TATI CA 125a
Patient no. (tLg l-') (Uml')
FIGO stage I 1 12 316
2 29 7
3 39 29
4 50 29
FIGO stage III 5 19 57
6 31 159
7 32 110
8 98 32
9 750 30
FIGO stage IV 10 87 371
aUpper normal level: TATI, 21 .tgml-'; CA 125, 35 U ml-'.
The only two patients (nos 1 and 5, Table II) with a false
negative TATI value had increased levels of CA 125. Thus,
the combination of TATI and CA 125 increased the sensi-
tivity and the negative predictive value to 100%. A slight
decrease in the corresponding specificity (89%) and positive
predictive value (86%) was registered.
Discussion
The lack of suitable methods for quantification of vital
tumour tissue is an impediment to the early diagnosis and
(successful?) management of ovarian cancer. Furthermore, it
is difficult to assess the effect of treatment during therapy and
in the follow-up period. Under these circumstances the
ovarian cancer-associated antigen CA 125 provides useful in-
formation (Finkler et al., 1988; Mogensen et al., 1988, 1989a;
Niloff et al., 1986; Van der Burg et al., 1988; Vergote et al.,
1987). However, increased CA 125 values are most common
in non-mucinous ovarian carcinomas and 50-60% of the
patients with mucinous tumours have false negative serum
antigen levels before the operation (Halila et al., 1988;
Maughan et al., 1988; Mogensen et al., 1989b). In accor-
dance with these findings, immunohistochemical studies have
demonstrated a lack of CA 125 reactivity in the mucinous
ovarian cancer tissue of 43-100% of the patients (Koelma et
al., 1987; Macdonald et al., 1988; Maughan et al., 1988;
Neunteufel & Breitenecker, 1988). Thus, most of these
tumours fail to produce this antigen, but the use of addi-
tional tumour markers may add useful diagnostic inform-
ation.
Recently, Halila et al. (1988) measured TATI in serum
drawn preoperatively from 45 patients with ovarian car-
cinomas and correlated the values with CA 125 measured in
the same samples. TATI was increased in 27% of the patients
and CA 125 in 82%. However, TATI was a better marker
than CA 125 in the mucinous tumours, of which 6/10 had
increased TATI levels and only 4/10 had abnormal CA 125
values.
The present study evaluated the usefulness of TATI,
separately and in combination with CA 125, as a diagnostic
tool in mucinous ovarian tumours. In accordance with Halila
et al. (1988), most (83%) malignant and borderline tumours
had increased TATI levels whereas only 50% had abnormal
CA 125 values. However, the combined use of the two
markers ensured diagnosis of all the malignant and border-
line tumours. This finding contrasted with the above study
(Halila et al., 1988) in which CA 125 did not supplement the
information derived from the TATI assay. However, FIGO
stage I patients formed 70% (7/10) in the series of Halila et
al. (1988) compared with 40% (4/10) in the current study and
this difference may explain the varying results. Furthermore,
the present investigation was performed in a small series as
mucinous tumour types only make up a small part of ovarian
carcinomas and a cautious interpretation of the results is
therefore advisable.
We do not yet know exactly why TATI levels are increased
in the serum of ovarian cancer patients. Abnormal marker
levels may be due to secretion of TATI from the tumour cells
(Halila et al., 1987) but increased TATI levels have also been
reported in patients with non-neoplastic diseases such as
hepatobiliary disease, pancreatitis and severe inflammation
(Haglund et al., 1986; Huhtala et al., 1983). In the present
study, one positive TATI and one positive CA 125 value
were demonstrated in two different benign cases and these
findings cannot be explained.
The number of patients with benign tumours having
positive tumour marker levels usually increases when more
than one marker is used for diagnostic purposes. Used alone
6% of the patients with benign tumours had positive TATI
values (specificity and positive predictive value 94% and
91%, respectively). In combination with CA 125 the number
of positive benign cases increased to 11% and the specificity
and positive predictive value decreased by only 5%.
In the present study, an increased TATI level was only
recorded in one out of 18 benign ovarian tumours. An
abnormal TATI content has been demonstrated in malignant
non-ovarian neoplasms such as uterine sarcoma and
endometrial, cervical and pancreatic cancer (Haglund et al.,
1986; Huhtala et al., 1983). Therefore, TATI may provide
information supplementing that derived from the CA 125
level; information which will be useful for preoperative
differential diagnosis of pelvic masses without significantly
increasing the number of false positive results. However,
studies including larger and consecutively collected series of
patients with pelvic tumours are necessary to elucidate this
problem.
In conclusion, as a diagnostic tool in mucinous ovarian
tumours TATI was a reliable tumour marker and a better
marker than CA 125. The best diagnostic results were
obtained by the combined use of TATI and CA 125, which
ensured diagnosis of all malignant and borderline tumours in
the present series.
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